Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults

Trial Profile

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Icatibant (Primary)
  • Indications Angioedema
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 28 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 15 May 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 Sep 2015.
    • 15 May 2015 According to the the ClinicalTrials.gov record, planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top